Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reolysin + GM-CSF in Pediatric Brain Tumors
NCT02444546Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jun 2015
- Primary completion
- Jul 2018
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pelareorep in glioma, medulloblastoma, Atypical teratoid rhabdoid tumor (ATRT) and 2 more, sponsored by Mayo Clinic. Primary endpoint: Maximum Tolerated Dose at 84 days. Started Jun 2015; status: completed.
02
Drugs
pelareorep
03
Conditions
gliomamedulloblastomaAtypical teratoid rhabdoid tumor (ATRT)primitive neuroectodermal tumor (PNET)diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT02444546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02444546.